Published 3 years ago • loading... • Updated 3 years ago

Treatments compared for pediatric-onset multiple sclerosis

Summary by Ground News

More patients with POMS are free of new or newly enlarging lesions with dimethyl fumarate. The annualized relapse rate is lower with DMF, according to a study in JAMA. Suicide risk is highest in the first three months after the dementia diagnosis.

2 Articles

All

Left

Center

Right

HealthDay

Center

Treatments Compared for Pediatric-Onset Multiple Sclerosis

THURSDAY, Oct. 6, 2022 (HealthDay News) -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate

3 years ago

Read Full Article

Medical Xpress

Center

Treatments compared for pediatric-onset multiple sclerosis

More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in JAMA Network Open.

3 years ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right